Christopher Frankenfield
Chief Operating Officer bij XILIO THERAPEUTICS, INC.
Vermogen: - $ op 31-03-2024
Oorsprong van het eerstegraads netwerk van Christopher Frankenfield
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 28 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Christopher Frankenfield via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Director of Finance/CFO Corporate Officer/Principal | |
ImClone LLC
 ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Biotechnology | Chief Executive Officer Corporate Officer/Principal | |
| JOHNSON & JOHNSON | Pharmaceuticals: Major | Corporate Officer/Principal Director of Finance/CFO | |
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| BIOGEN INC. | Pharmaceuticals: Major | Director of Finance/CFO Public Communications Contact | |
| ALEXION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO | |
| CUBIST PHARMACEUTICALS INC | Pharmaceuticals: Major | General Counsel Public Communications Contact Chief Tech/Sci/R&D Officer | |
| EXACT SCIENCES CORPORATION | Medical Specialties | Director/Board Member | |
Bioverativ Therapeutics, Inc.
 Bioverativ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bioverativ Therapeutics, Inc. develops pharmaceutical products. It develops medicines for chronic diseases such as hemophilia, anemia, multiple sclerosis, and autoimmune disorders. The company is headquartered in Cambridge, MA. | Pharmaceuticals: Major | President | |
| MERSANA THERAPEUTICS, INC. | Biotechnology | Director/Board Member Chief Executive Officer Director/Board Member | |
Stromedix, Inc.
 Stromedix, Inc. Pharmaceuticals: MajorHealth Technology Stromedix, Inc. develops novel drugs to treat fibrosis and fibrotic organ failure. The company was founded by Michael Gilman in 2006 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| SYNDAX PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member | |
| TESARO INC | Pharmaceuticals: Major | Director of Finance/CFO General Counsel Chief Tech/Sci/R&D Officer Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Johnson & Johnson Innovation - JJDC, Inc.
 Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | Investment Managers | Private Equity Analyst President | |
| GSK PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Duke University
 Duke University Other Consumer ServicesConsumer Services Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC. | College/University | Undergraduate Degree Undergraduate Degree | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Doctorate Degree Undergraduate Degree | |
| Stanford University | College/University | Undergraduate Degree Undergraduate Degree | |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Pharmaceuticals: Major | Corporate Officer/Principal | |
| BLUEBIRD BIO, INC. | Biotechnology | Chairman Corporate Officer/Principal | |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor Consultant / Advisor | |
DuPont Merck Pharmaceutical Co.
 DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a private company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| King's College (Pennsylvania) | College/University | Undergraduate Degree | |
Northeastern University
 Northeastern University Other Consumer ServicesConsumer Services Founded in 1898, Northeastern University is a private research university located in the heart of Boston. Northeastern teaches worldwide experiential learning, urban engagement, and interdisciplinary research that meets global and societal needs. The University offers a range of undergraduate and graduate programs leading to degrees through the doctorate in nine colleges and schools. | College/University | Graduate Degree Undergraduate Degree | |
| AMAG PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Chief Administrative Officer | |
| Harvard Medical School | College/University | Doctorate Degree Graduate Degree | |
| BLUEPRINT MEDICINES CORPORATION | Biotechnology | Chairman Chief Operating Officer | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin | |
| Columbia Business School | College/University | Masters Business Admin | |
| EDITAS MEDICINE, INC. | Biotechnology | Director of Finance/CFO Corporate Officer/Principal | |
| University of Pennsylvania Medical Center | College/University | Doctorate Degree | |
| CYTOMX THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| SURFACE ONCOLOGY, INC. | Biotechnology | Chief Executive Officer Chief Executive Officer President | |
| LEGEND BIOTECH CORPORATION | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Stargazer Pharmaceuticals, Inc.
 Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Stargazer Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm engages in the development of treatment for Stargardt’s disease, a rare form of juvenile, retinal degeneration. The company was founded by Gary Jay Sternberg and is headquartered in Boston, MA. | Pharmaceuticals: Major | Director/Board Member | |
| AKERO THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| PYXIS ONCOLOGY, INC. | Pharmaceuticals: Major | Director/Board Member | |
Tio Bioventures
 Tio Bioventures Investment ManagersFinance Tio Bioventures (Tio Bioventures) is a venture capital firm founded in 2019 by Tak Wah Mak and Shane Burgess. The firm is headquartered in New York. | Investment Managers | Chief Tech/Sci/R&D Officer | |
Asylia Therapeutics, Inc.
 Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | Pharmaceuticals: Major | Director/Board Member | |
| INVIVYD, INC. | Biotechnology | Director/Board Member Founder | |
| BCLS ACQUISITION CORP. | Financial Conglomerates | Director of Finance/CFO Director/Board Member | |
Sionna Therapeutics, Inc.
 Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | Medical/Nursing Services | Chairman | |
Sporos Bioventures, Inc.
 Sporos Bioventures, Inc. Medical/Nursing ServicesHealth Services Sporos Bioventures, Inc. is a private biopharmaceutical company based in Houston, TX. Sporos Bioventures, Inc. aims to transform the drug development process by identifying novel disease mechanisms and strategically deploying talent, capital, and access to operational resources to catalyze the development of breakthrough medicines. Sporos' current pipeline is diversified across three business units and includes multiple clinical-stage candidates that are being investigated for the treatment of multiple indications in cancer and immune disease. The company provides centralized expertise, resources, and core infrastructure so that the portfolio companies can focus primarily on their research development programs. The company was founded by Peter Feinberg, Ronald A. DePinho, Jeno Gyuris, Joseph Kekst, Harold Levy, Alex M. Cranberg, Louis Feinberg, Michael S. Wyzga, Dana Levy, and the CEO is Stephen Rubino. | Medical/Nursing Services | Director/Board Member | |
| EFFECTOR THERAPEUTICS, INC. | Biotechnology | Corporate Officer/Principal | |
Xilio Therapeutics LLC
 Xilio Therapeutics LLC Pharmaceuticals: MajorHealth Technology Part of Xilio Therapeutics, Inc., Xilio Therapeutics LLC develops cancer biopharmaceuticals. The private company is based in Waltham, MA. The CEO of the company is René Russo. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Oak Hill Bio Corp.
 Oak Hill Bio Corp. Miscellaneous Commercial ServicesCommercial Services Oak Hill Bio, Inc. is a clinical-stage rare disease therapeutics company. It develops life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. The firm has operations in the United States and United Kingdom to develop a pipeline of clinical-stage and pre-clinical investigational therapeutics acquired and licensed from Takeda Pharmaceutical Company Limited. The company is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Director/Board Member | |
Normunity, Inc.
 Normunity, Inc. Miscellaneous Commercial ServicesCommercial Services Normunity, Inc. is a biotechnology company that creates precision immuno-oncology medicines called immune normalizers. The company is based in West Haven, CT and has subsidiaries in the United States. These medicines target novel mechanisms that free the body's normal immunity against cancer. Normunity is based on an ongoing academic-biotech partnership with the lab of Dr. Lieping Chen at Yale School of Medicine. The company is advancing an emerging pipeline of immune normalizers, including initial drug programs that target mechanisms that drive the exclusion of T-cells from immune-sensitive tumors and other mechanisms that are barriers to normal immune function in cancer. The CEO of the company is Rachel W. Humphrey. | Miscellaneous Commercial Services | Chief Executive Officer | |
| ALLENA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Corporate Officer/Principal |
Statistieken
Internationaal
| Verenigde Staten | 47 |
| Verenigd Koninkrijk | 3 |
| Japan | 2 |
| Kaaimaneilanden | 2 |
Sectoraal
| Health Technology | 34 |
| Consumer Services | 10 |
| Finance | 5 |
| Health Services | 3 |
| Commercial Services | 3 |
Operationeel
| Director/Board Member | 122 |
| Corporate Officer/Principal | 56 |
| Independent Dir/Board Member | 48 |
| Chairman | 28 |
| Chief Executive Officer | 25 |
Sterkste connecties
| Insiders | |
|---|---|
| Michael Ross | 44 |
| Daniel Lynch | 32 |
| Dave Grayzel | 23 |
| Andrew Hack | 20 |
| Tomas Jan Heyman | 18 |
| Rachel Humphrey | 17 |
| Allene Diaz | 14 |
| Paul Clancy | 14 |
| René Russo | 11 |
| Joseph Farmer | 10 |
| Martin Huber | 10 |
| Timothy D. Hunt | 10 |
| Daniel Curran | 10 |
| Sara Bonstein | 9 |
| Yuan Xu | 9 |
- Beurs
- Insiders
- Christopher Frankenfield
- Bedrijfsconnecties
